U.S. RESEARCH ROUNDUP- Equifax, Microstrategy, Netflix

Reuters11-19

Nov 19 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Equifax, Microstrategy and Netflix, on Tuesday.

HIGHLIGHTS

* Caseys General Stores Inc : Jefferies raises target price to $470 from

$450

* Equifax Inc : JP Morgan cuts target price to $283 from $304

* Microstrategy Inc : Benchmark raises target price to $450 from $300

* Netflix Inc : Jefferies raises target price to $1,000 from $800

* Palo Alto Networks Inc : Jefferies raises target price to $450 from $400

Following is a summary of research actions on U.S. companies reported by Reuters on Tuesday. Stock entries are in alphabetical order.

* Aclaris Therapeutics Inc : BTIG raises to buy from neutral

* Aclaris Therapeutics Inc : Jefferies raises to buy from hold

* Aclaris Therapeutics Inc : Jefferies raises target price to $7 from $2

* Aclaris Therapeutics Inc : Piper Sandler raises to overweight from neutral

* Aclaris Therapeutics Inc : Piper Sandler raises target price to $13 from $3

* Arvinas : Stephens initiates coverage with overweight rating; target price $55

* Beacon Roofing Supply Inc : JP Morgan raises target price to $136 from $119

* C4 Therapeutics : Stephens initiates coverage with equal-weight rating; PT $4

* Caseys General Stores Inc : Jefferies raises target price to $470 from $450

* Catalyst Pharmaceuticals : Stephens initiates coverage with overweight rating; PT $35

* Chargepoint Holdings Inc : HSBC cuts target price to $1.2 from $2

* Copart Inc : JP Morgan raises target price to $60 from $55

* Cullinan Therapeutics Inc : Jonestrading raises target price to $34 from $29

* Dime Community Bancshares : Stephens raises to overweight from equal-weight

* Dime Community Bancshares : Stephens raises target price to $39 from $30

* Enhabit Inc : Jefferies cuts target price to $8.25 from $8.75

* Equifax Inc : JP Morgan cuts target price to $283 from $304

* Fennec Pharmaceuticals : Stephens initiates coverage with overweight rating; PT $15

* Fortinet Inc : Piper Sandler raises target price to $100 from $80

* Franco-Nevada Corp : UBS initiates coverage with buy rating; target price $160

* Ideaya Biosciences : Stephens initiates coverage with overweight rating; PT $51

* Kemper Corp : TD Cowen raises target price to $84 from $72

* Kraft Heinz : Piper Sandler cuts to neutral from overweight

* Kraft Heinz : Piper Sandler cuts target price to $35 from $40

* Kymera Therapeutics : Stephens initiates coverage with overweight rating; PT $65

* Lovesac Co : Roth MKM raises target price to $35 from $31

* Methanex Corp : Piper Sandler raises target price to $71 from $68

* Microstrategy Inc : Benchmark raises target price to $450 from $300

* Microstrategy Inc : TD Cowen raises target price to $392 from $385

* Moderna : Berenberg initiates coverage with hold rating; target price $42

* Mosaic Co : Berenberg raises target price to $32 from $30

* Netflix Inc : Jefferies raises target price to $1,000 from $800

* Netflix Inc : Wedbush raises target price to $950 from $800

* Palo Alto Networks Inc : Jefferies raises target price to $450 from $400

* Plug Power Inc : HSBC cuts target price to $3.7 from $7.1

* PTC Therapeutics Inc : JP Morgan raises target price to $62 from $51

* Quantumscape Corp : HSBC raises target price to $5.3 from $4.7

* Quantumscape Corp : HSBC raises to hold from reduce

* Ready Capital Corp : KBW cuts target price to $6.75 from $7

* Reddit : Piper Sandler raises target price to $150 from $115

* Regenxbio Inc : Leerink Partners raises target price to $38 from $34

* Suncor Energy Inc : UBS raises target price to C$65 from C$61

* Vertiv Holdings Co : Jefferies raises target price to $145 from $125

* Williams-Sonoma Inc : JP Morgan raises target price to $145 from $136

(Compiled by Bengaluru Newsroom)

((Diaries@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment